A naturally occurring antibody measured before combat deployment was associated with lower depression and post-traumatic stress scores among Marines who later reported a traumatic brain injury, UC San Diego researchers found. The result identifies a possible biological marker for resilience after brain injury; it does not establish that the antibody protected anyone or that increasing it would be safe or useful.
The analysis followed 1,025 active-duty male Marines in the Marine Resiliency Study II before and after a seven-month Afghanistan deployment between 2011 and 2013. Researchers classified 606 participants as having experienced a traumatic brain injury and 419 as having no TBI. Most of the reported injuries were mild, an important boundary for interpreting the findings.
The protein is a natural autoantibody against the N-methyl-D-aspartate receptor 1, or NMDAR1. That receptor helps nerve cells communicate and is involved in learning, memory and stress responses. Autoantibodies are immune proteins that recognize the body's own molecules. Their presence is not automatically a disease signal; concentration, antibody class and access to the brain can matter.
Among participants with a TBI, those in the highest quarter of predeployment antibody levels had adjusted depression scores about 25 percent lower and PTSD scores about 22 percent lower after deployment than those with lower levels. The release describes those differences as roughly two points for depression and four points for PTSD. Antibody levels were not associated with anxiety scores, and the same depression and PTSD pattern did not appear in the group without a TBI.
A separate statistical comparison found lower odds of moderate-to-severe depression in the high-antibody TBI group. The estimate was strong, but its confidence interval was wide, reflecting uncertainty about the precise size of the association. That distinction matters: a biomarker can correlate with an outcome even when it is not the mechanism producing it.
Measurements in a subset of 236 participants were relatively stable over 10 to 12 months. Researchers proposed that the antibodies' IgM form may remain largely outside an intact blood-brain barrier while helping clear circulating receptor fragments after injury. That is a biological explanation to test, not a clinical instruction. The study did not give participants an antibody treatment or manipulate their levels.
The cohort also narrows what can be claimed. All participants were men serving in infantry roles, TBI history was self-reported and the deployments occurred more than a decade ago. Results may differ for women, civilians, severe injuries, older adults or people with other medical conditions. Observational data can adjust for measured differences, but unmeasured factors may still connect antibody level and symptom severity.
The paper appeared in Molecular Psychiatry, and UC San Diego disclosed that senior author Xianjin Zhou is an inventor on a provisional university patent related to the finding. Replication in broader cohorts would need to come before a diagnostic threshold or therapy. For now, the useful result is narrower: one predeployment blood measure separated average postdeployment symptom levels within the TBI group, giving researchers a candidate pathway to investigate rather than a ready-made shield against trauma.